Skip to main content

FDA Updates

FDA Approves Tepmetko for Metastatic NSCLC and MET Exon 14 Skipping Alterations

Xpovio Approved for Patients with Relapsed or Refractory Multiple Myeloma

Tagrisso Receives New Indication as Adjuvant Therapy for NSCLC with EGFR Mutations

Xalkori Approved for Anaplastic Large-Cell Lymphoma and ALK Mutation in Young Patients

FDA Approves Margenza for the Treatment of Metastatic HER2-Positive Breast Cancer

Orgovyx First FDA-Approved Oral Hormone Therapy for Advanced Prostate Cancer

FDA Approves First Prostate-Specific Membrane Antigen–Targeted PET Imaging Drug for Prostate Cancer

Danyelza First Drug FDA Approved for High-Risk Neuroblastoma in the Bone and Bone Marrow

Gavreto, a New RET Inhibitor, FDA Approved for Metastatic NSCLC with RET Fusions

Onureg FDA Approved for Adults with AML in Remission

11
12
13
14
15
16
17

Page 14 of 33
Results 131 - 140 of 330